BioPorto Reports 11% Revenue Growth in 2025 Amid Rising Losses
Event summary
- BioPorto reported DKK 40.3 million in total revenue for 2025, an 11% increase from 2024, driven by 22% growth in NGAL revenues.
- Adjusted EBITDA loss widened by 8% to DKK 76.5 million, within the company's guidance range.
- Cash position declined by 8% to DKK 54.9 million as of December 31, 2025.
- Company completed patient enrollment in its ProNephro AKI (NGAL) study for adult use in October 2025.
- BioPorto raised DKK 76.5 million through private placements in 2025.
The big picture
BioPorto's 2025 results show steady revenue growth in its NGAL biomarker business, particularly in the US market, but widening losses highlight the challenges of scaling a diagnostics company. The completion of patient enrollment in its ProNephro AKI study marks a critical step toward potential FDA approval, which could significantly expand its addressable market. The company's ability to secure financing and execute its Forward strategy will be key to achieving its ambitious 2028 targets.
What we're watching
- Regulatory Progress
- Whether BioPorto's pre-submission meeting request to the FDA will accelerate ProNephro AKI approval timeline.
- Financial Sustainability
- How the company will manage its widening EBITDA loss while maintaining positive cash flow expectations for 2027.
- Market Expansion
- The pace at which BioPorto can achieve its 2028 revenue target of DKK 150-200 million through its Forward strategy.
Related topics